HIMS Shorts Ease, But CEO's Stake Keeps Shrinking

Hims & Hers Health heads into its November 2 earnings report with a founder reducing his stake, shorts stubbornly high but quietly pulling back, and a Street consensus that has yet to commit to the growth story.

The most newsworthy structural fact about HIMS right now is the activist register. Andrew Dudum, the company's CEO and co-founder, filed a Schedule 13D/A in August showing his stake had fallen to 9.4% from 10.3% previously. The 13D classification matters: it signals a holder with influence over the company, not a passive investor, and the direction of travel is downward. His institutional holding count puts him at 16.6 million shares as of late August, a decline of 1.36 million from the prior report. Per ORTEX's disclosure, stakes on the 13D/G register are as-last-disclosed around the 5% threshold, and a holder can exit further without a new filing until they cross back into the window. At the same time, recent insider trades filed with the SEC show the CFO, CLO and COO all selling shares through pre-arranged 10b5-1 plans over September and October. All were plan-based sales, which reduces the signal value, but the net insider position over the past 90 days is negative $3.96 million across roughly 138,000 shares. There is no offsetting buy pressure from the C-suite.

Short positioning is genuinely large but has been slowly unwinding. Short interest now stands at 24.3% of the free float, roughly 53.2 million shares, down from a peak near 58 million in early September. The week-on-week change is a reduction of about 2.2%, and the month-on-month move is a decline of 4.5%. That matters because the borrow market tells the same story: availability has loosened to 88.4%, close to the 52-week high of 92.1%, meaning new shorts face little friction entering the trade but the trend in the existing position is toward modest covering. Cost to borrow has fallen 25% over the past month to just 0.51%, a low level that removes squeeze pressure as a near-term risk. Options traders are equally calm. The put/call ratio is 0.54, fractionally below its 20-day average and well off the 52-week high of 1.14, placing it near the most call-heavy extreme in the past year. That combination, high but declining short interest, loose borrow, and call-skewed options, does not describe a stock under acute bearish pressure. It describes one where the bears already have their positions on and have stopped adding.

The Street has not found conviction in either direction. Twelve analysts rate the stock Hold, and the most recent coverage initiation came from JP Morgan in September with a Neutral rating and a $32 target. After August earnings, a cluster of firms raised targets: Morgan Stanley moved from $21 to $28, BofA from $30 to $32, Needham from $35 to $42. Barclays was the outlier, cutting its Overweight target from $39 to $35. With the stock at $29.21, the mean target sits in the low-to-mid $30s, representing modest upside, but the unanimous Hold consensus is a signal that the Street respects the growth without being willing to underwrite the multiple. The bull case rests on 38% revenue growth to $753 million in Q2, a subscriber base of 2.89 million, and AI tools that the company says have cut support workload by around 50%. The bear case points to gross margin compressing to 63.8%, negative free cash flow of $68 million in Q2, and a debt pile of $1.37 billion against $841 million in cash, with margin pressure showing no near-term floor. The EV/EBITDA multiple has crept up to 19.4x over the past month even as earnings surprise ranks in the bottom 1% of the universe on ORTEX's factor scoring. The forward earnings revision score is the bright spot, ranking in the 61st percentile, but the short score rank sits in the 5th percentile, meaning the stock screens as one of the more heavily shorted names in the database.

Earnings reactions have been asymmetric. The August Q2 print produced a 3.4% drop the next day and a 9.4% decline over the following five sessions, while the prior report in early May triggered a 15.8% gain on the day. That range, nearly 20 points between the two most recent outcomes, reflects how binary this story has become: the company either exceeds on both growth and margin trajectory, or the compression narrative wins. With Q3 results due November 2 and the stock down 1.7% on the week against a flat median for its closest correlated peers, the setup heading into the print is one to watch for any shift in Dudum's disclosed stake and whether the short covering trend resumes or reverses around that date.